Fred Saad, MD, CQ, FRCS, FCAHS, discusses additional efficacy data from the phase 3 PSMAddition trial, evaluating the addition of 177Lu-PSMA-617 to standard of care ADT plus an ARPI in PMSA+ mHSPC.
Fred Saad, MD, CQ, FRCS, FCAHS
Advertisement
Articles by Fred Saad, MD, CQ, FRCS, FCAHS
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Urology Times
1
Unmet needs and emerging solutions in MRI-guided prostate cancer care
2
Enzalutamide plus talazoparib demonstrates clinical activity in mHSPC
3
Mina Fam, MD, highlights significance of tebipenem pivoxil approval for cUTI
4
Pearls & Perspectives: The Power of Advocacy in Sexual Medicine, With Rachel Rubin, MD
5